Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid) on top of beta-blockers, on central aortic blood pressure. Randomized, cross-over, double blind, multicentre, study over 10 weeks in patients with stable coronary artery disease, type II diabetes and a resting heart rate equal or superior to 70 bpm, already treated with beta-blockers.
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2015
At a glance
- Drugs Ivabradine (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Servier
- 31 May 2014 Status changed from recruiting to discontinued as reported by EudraCT record.
- 04 May 2012 New trial record